Galapagos NV: business update: http://t.co/6w1jppWE
posted 5 days ago
FlandersBio offers an up-to-date life sciences database containing all the life sciences companies with biotech activity in Flanders, and all FlandersBio members. The guide provides easy and fast access to the local life sciences community.
Website: http://www.pharmaneuroboost.com
Email:
Phone: +32 11 48 07 50
FlandersBio Member
More address details
The CNS Company PharmaNeuroBoost has two proprietary products in late clinical development stage: the antidepressant (AD) PNB01 in Phase III and the antipsychotic PNB02 in Phase IIa. The PNB01 phase III program is granted with a Special Protocol Assistance (SPA) from FDA. If successful, PNB01 would be the first AD claiming an early response, addressing the unmet medical need of latency of response of current AD's. As such, PNB01 could have a potential step up into a large and lucrative market.
PharmaNeuroBoost (PNB) - founded end 2006 by Dr. Erik Buntinx, psychiatrist and inventor of PNB's technology - is a specialty biopharmaceutical company dedicated to developing best in class CNS therapeutics. As such, PNB is specialized in boosting current standard of care on major CNS disorders addressing high unmet medical needs.
The company is managed by CEO Erik Buntinx. He is currently assisted with a core group of 7 key top specialists – Ludo Haazen, MD, CMO, Remi Van Den Broeck, MD-MSc, CDO, Didier de Chaffoy, PhD, CSO, Philippe Lemmens, PhD, Director Clinical Development, Lieven Baert, PhD, MBA, Director CMC, Arthur Noach, PhD, Director Non-Clinical and Patricia Baede, PhD, Director Regulatory Affairs – and uses a virtual model, contracting drug development people in as required, with an aim to remain dynamic and efficient.
PNB’ Business Plan is oriented to collaborate with high value partners for co-development and/or commercialization of the late stage products.
PNB has brought two proprietary products in late and mid clinical development stage: the antidepressant PNB01 in Phase III and the antipsychotic PNB02 in Phase IIa.
These two front-running projects result from discoveries made using PNB's unique IP platform claiming the use of high selective Serotonin 2A / Dopamine 4 receptor antagonists. In that respect, PNB has globally (US, Canada, Europe and Japan) granted Composition of Matter (CoM) and use patents for the individual compounds in its pipeline.
The lead product PNB01, a novel antidepressant (AD) with an early and sustained response (ESR), has entered globally (US, Canada and Europe) phase III in August 2011 after FDA and IRB approval of the study protocol. This includes ESR as the new, unique primary end point demonstrating the superiority of PNB01 over standard of care.
This phase III program is granted with a Special Protocol Assistance (SPA) from FDA.
If successful, PNB01 would be the first AD claiming an early response, addressing the unmet medical need of latency of response of current AD's.
PNB's second product PNB02, has entered phase II in March 2012, and is targeted against the residual phase of schizophrenia, a high unmet medical need up till date.
Recent and Upcoming Company Highlights are:
PNB has already established R&D co-operations with several national and international partners i.e.
Address:
Alkerstraat 30A
3570
Alken
Belgium
Route: Via Google Maps
Website: http://www.pharmaneuroboost.com
Phone: +32 11 48 07 50
Fax: +32 11 48 49 23
Foundation date: 2006
Email: info@pharmaneuroboost.com
Sorry, to find this company's location on Google Maps, Javascript is required.
